LAMATTINA JOHN L 4

What Happened

• John L. LaMattina, a director of Ligand Pharmaceuticals, sold a total of 4,591 shares in open-market transactions on June 10, 2026, generating approximately $1,151,774 in proceeds. The individual transactions reported were:
  • 257 shares at a weighted-average price of $247.22 — $63,536
  • 232 shares at a weighted-average price of $248.11 — $57,562
  • 697 shares at a weighted-average price of $249.53 — $173,924
  • 3,405 shares at a weighted-average price of $251.62 — $856,752
• These were sales (not purchases or option exercises), which are often routine insider transactions and do not by themselves indicate company performance or insider sentiment.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (appears timely).
• Aggregate proceeds: ≈ $1,151,774 for 4,591 shares.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: Each reported price is a weighted-average. Footnotes note that the shares were sold in multiple executions at price ranges (e.g., $246.63–$247.61; $247.94–$248.335; $249.34–$250.27; $250.91–$251.895). The reporting person will provide a breakdown of the number of shares sold at each price upon request.
• No indication in this filing of a 10b5‑1 plan, option exercise, gift, or tax-withholding disposition.

Context

• Sales by directors can be for many personal reasons (diversification, taxes, liquidity) and are common; they are less informative than insider purchases when assessing insider conviction.
• The filing shows straightforward open-market sales rather than derivative transactions or awards; no cashless exercise or immediate resale of exercised shares is involved.